Related Experiment Videos
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Brad Spellberg1, John Edwards, Ashraf Ibrahim
1Department of Medicine, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance, 1124 West Carson St. RB2, Torrance, CA 90502, USA. bspellberg@labiomed.org
Clinical Microbiology Reviews
|July 16, 2005
Summary
Mucormycosis, a severe fungal infection in immunocompromised individuals, is increasingly common with poor survival. Understanding iron
Area of Science:
- Mycology
- Immunocompromised Host Pathogenesis
- Infectious Diseases
Background:
- Mucormycosis is a life-threatening fungal infection predominantly affecting immunocompromised patients.
- Increasing incidence and high mortality rates underscore the urgent need for improved therapeutic strategies.
- Iron metabolism is a critical factor in mucormycosis pathogenesis, with deferoxamine posing a risk by supplying iron to the fungus.
Purpose of the Study:
- To explore the role of iron metabolism in mucormycosis.
- To evaluate novel therapeutic strategies for mucormycosis.
- To highlight key principles for managing mucormycosis.
Main Methods:
- Review of current literature on mucormycosis pathogenesis and treatment.
- Analysis of the role of iron metabolism and iron chelators.
- Evaluation of established and emerging antifungal therapies.
Main Results:
- Iron metabolism is central to mucormycosis, and certain iron chelators may exacerbate infection.
- High-dose liposomal amphotericin B is a preferred monotherapy.
- Combination therapies (e.g., lipid amphotericin B with echinocandins or azoles) and novel strategies show promise.
Conclusions:
- Targeting iron metabolism with appropriate chelators may offer new therapeutic avenues.
- Liposomal amphotericin B remains a cornerstone of treatment, with combination therapies providing alternative options.
- Effective mucormycosis management requires rapid diagnosis, addressing predisposing factors, and prompt surgical intervention.